Form 4: Edgewise Therapeutics Director Receives Stock Award
Statement of Changes in Beneficial Ownership
Jonathan C. Fox, a Director at Edgewise Therapeutics, Inc., received a restricted stock unit award on July 1, 2026, as part of his quarterly retainer.
Summary
- Jonathan C. Fox, a Director of Edgewise Therapeutics, Inc., was granted 319 shares of common stock on July 1, 2026.
- This grant was in the form of restricted stock units (RSUs) released to him on the same date.
- The award is designated as a Quarterly Retainer Award under the company's Outside Directors Compensation Policy.
- Following this transaction, Mr. Fox beneficially owns 24,833 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a company director and does not contain new financial performance data or strategic shifts.
Positives
- Director compensation is being provided in the form of equity, aligning director interests with shareholders.
- The transaction is a routine retainer award, indicating ongoing engagement and compensation for board service.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a director's compensation award.
Industry Context
StockSavvy.ai notes that the issuance of restricted stock units as a quarterly retainer for directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced board members by aligning their incentives with long-term company performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy | Grant of restricted stock units as a Quarterly Retainer Award pursuant to Section 2.4 of the Outside Directors Compensation Policy, as amended. | 07/01/2026 | Standard compensation practice for directors, reinforcing alignment with company performance. |
Related Party Transactions
- The transaction involves a director of the company receiving equity compensation, which is a related party transaction disclosed under SEC regulations.
Stakeholder Impact
- Shareholders: The issuance of stock awards dilutes existing ownership slightly but aligns director incentives with shareholder value creation.
- Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board.
- Management: The filing is a routine disclosure related to board compensation.
Key Dates
| Date | Description |
|---|---|
| 07/01/2026 | Date of transaction (grant and release of restricted stock units) and earliest transaction date. |
Keywords
Edgewise Therapeutics, EWTX, Form 4, Director Compensation, Restricted Stock Units, Equity Award, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.